Johnson & Johnson 4Q Revenues: $18.1 billion (+2%) 4Q Earnings: $3.8 billion (+19%) FY Revenues: $71.9 billion (+3%) FY Earnings: $16.5 billion (+7%) Comments: Worldwide Pharmaceutical sales were $33.5 billion for the year, up 7%. Domestic sales increased 10% and international sales increased 2%. Strong growth in new products include IMBRUVICA ($1.3 billion, up 82%), for use in treating certain B-cell malignancies; DARZALEX ($572 million), for the treatment of multiple myelom...